0

Axitinib

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP319460850
CAS319460-85-0
Structure
MDL NumberMFCD09837898
Molecular Weight386.47
InChI KeyRITAVMQDGBJQJZ-FMIVXFBMSA-N
Description≥98% (HPLC)
SolubilityDMSO: ≥8 mg/mL
Assay≥98% (HPLC)
Colorwhite to tan
Formpowder
Size5MG
Storage Conditionsroom temp
1

Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura, Jae L Lee, Aleksandr Vasiliev, etc.

N Engl J Med. 2019 Mar 21;380(12):1103-1115.

PMID: 30779531

1

Axitinib in Combination With Pembrolizumab in Patients With Advanced Renal Cell Cancer: A Non-Randomised, Open-Label, Dose-Finding, and Dose-Expansion Phase 1b Trial

Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi, Brad Rosbrook, Kathrine C Fernandez, etc.

Lancet Oncol. 2018 Mar;19(3):405-415.

PMID: 29439857

1

Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, etc.

Lancet. 2011 Dec 3;378(9807):1931-9.

PMID: 22056247

1

Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, etc.

N Engl J Med. 2019 Mar 21;380(12):1116-1127.

PMID: 30779529

1

Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients With Advanced Clear-Cell Renal-Cell Carcinoma (JAVELIN Renal 100): An Open-Label, Dose-Finding and Dose-Expansion, Phase 1b Trial

Toni K Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David McDermott, Paul B Robbins, David D Chism, Daniel Cho, Michael B Atkins, Michael S Gordon, etc.

Lancet Oncol. 2018 Apr;19(4):451-460.

PMID: 29530667

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode